3DP 3534

Drug Profile

3DP 3534

Alternative Names: GW 395058; PEG-TPO

Latest Information Update: 02 Nov 2005

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer 3-Dimensional Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombocytopenia

Most Recent Events

  • 02 Nov 2005 No development reported - Preclinical for Thrombocytopenia in United Kingdom (unspecified route)
  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
  • 06 Mar 2002 3-Dimensional Pharmaceuticals have announced a collaboration agreement with Inhale Therapeutic Systems
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top